Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon.
Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Hum Genet. 2022 Jun;141(6):1159-1164. doi: 10.1007/s00439-021-02260-9. Epub 2021 Feb 9.
While significant advances have been made in pharmacogenetics (PGx), especially in countries with developed economies, this field remains at its infancy in developing countries and low resource environments. Herein, we provide insights into the gap and challenges of PGx at the research and clinical fronts, and some perspectives to bridge the gap and move forward with PGx in the developing world. We show that developing countries fall behind in PGx research, evidenced by a lower number of researchers, citations, and research output. In addition, the implementation of PGx in the clinic has been progressing at a much slower pace than research, and more so in developing countries. To bridge this gap, we recommend fostering regional and multinational collaborations to secure funds for high-throughput genotyping and local capacity building while preserving individual countries' identity, implementing next-generation sequencing, and organizing specialized training and exchange programs to move PGx research and clinical applications forward in developing countries.
尽管在药物遗传学（PGx）方面取得了重大进展，尤其是在发达经济体的国家，但该领域在发展中国家和资源匮乏环境中仍处于起步阶段。在此，我们深入探讨了 PGx 在研究和临床前沿方面的差距和挑战，以及一些弥合差距并推动发展中国家 PGx 发展的观点。我们发现，发展中国家在 PGx 研究方面落后，具体表现为研究人员、引文和研究成果数量较少。此外，PGx 在临床上的实施进展比研究要慢得多，在发展中国家更是如此。为了弥合这一差距，我们建议促进区域和跨国合作，为高通量基因分型和当地能力建设筹集资金，同时保持各国的特色，实施下一代测序，并组织专门的培训和交流计划，以推动发展中国家 PGx 研究和临床应用的发展。
